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Enterococcal bacteraemia: factors inﬂuencing mortality, length of stay and costs of
hospitalization
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Abstract
Enterococci are a major cause of nosocomial bacteraemia. The impacts of vanB vancomycin resistance and antibiotic therapy on outcomes in
enterococcal bacteraemia are unclear. Factors that affect length of stay (LOS) and costs of managing patients with enterococcal bacteraemia
are also unknown. This study aimed to identify factors associated with mortality, LOS and hospitalization costs in patients with enterococcal
bacteraemia and the impact of vancomycin resistance and antibiotic therapy on these outcomes. Data from 116 patients with vancomycin-
resistant Enterococci (VRE), matched 1:1 with patients with vancomycin-susceptible Enterococcus (VSE), from two Australian hospitals were
reviewed for clinical and economic outcomes. Univariable and multivariable logistic and quantile regression analyses identiﬁed factors
associated with mortality, LOS and costs. Intensive care unit admission (OR, 8.57; 95% CI, 3.99–18.38), a higher burden of co-morbidities
(OR, 4.55; 95% CI, 1.83–11.33) and longer time to appropriate antibiotics (OR, 1.02; 95% CI, 1.01–1.03) were signiﬁcantly associated with
mortality in enterococcal bacteraemia. VanB vancomycin resistance increased LOS (4.89 days; 95% CI, 0.56–11.52) and hospitalization costs
(AU$ 28 872; 95% CI, 734–70 667), after adjustment for confounders. Notably, linezolid deﬁnitive therapy was associated with lower
mortality (OR, 0.13; 95% CI, 0.03–0.58) in vanB VRE bacteraemia patients. In patients with VSE bacteraemia, time to appropriate antibiotics
independently inﬂuenced mortality, LOS and hospitalization costs, and underlying co-morbidities were associated with mortality. The study
ﬁndings highlight the importance of preventing VRE bacteraemia and the signiﬁcance of time to appropriate antibiotics in the management of
enterococcal bacteraemia.
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